Laurus Labs Ltd

Laurus Labs Merger & Restructuring Worth ₹107.8 Cr

Laurus Labs approved an investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support the setup of a manufacturing facility. Additionally, the company announced two independent director appointments and the voluntary closure of its step-down German subsidiary.

Value

₹107.8 Cr

Execution

Financial year 2026-27

Laurus Labs Q4 FY26 Results: Net Profit ₹282.1 Cr, Up 21.2% YoY

Laurus Labs Ltd reported revenue from operations of ₹1,812 Cr (+5.3% YoY) and net profit of ₹282.1 Cr (+21.2% YoY) for Q4 FY26.

Key figure

Net profit ₹282.1 Cr · +21.2% YoY

Laurus Labs Financial Results

Laurus Labs Limited reported audited consolidated financial results for FY 2025-26, with annual total income reaching ₹6,867.85 Crore. The Board approved a second interim dividend of ₹1.20 (60%) per equity share for FY 2025-26, with a record date of May 08, 2026. The 21st AGM is scheduled for July 02, 2026.

Laurus Labs Results Correction

Laurus Labs Limited clarified deficiencies in its October 23, 2025 financial results submission. The company addressed technical issues regarding machine-readable formats and XBRL discrepancies due to portal glitches. It confirmed that revised and correct XBRL filings have been submitted to the exchange to rectify the inadvertent selection of half-yearly figures.

Laurus Labs Q3 FY26 Results: Net Profit ₹252 Cr, Up 171.3% YoY

Laurus Labs Ltd reported net profit of ₹252 Cr (+171.3% YoY) for Q3 FY26.

Key figure

Net profit ₹252 Cr · +171.3% YoY

Laurus Labs Board Meeting Outcome

Laurus Labs Limited has scheduled a board meeting for April 30, 2026, to consider audited financial results for the year ended March 2026 and an interim dividend. The trading window for designated persons is closed from April 1, 2026, until May 2, 2026.

Laurus Labs Board Meeting Outcome

Laurus Labs Ltd has scheduled a Board meeting on April 30, 2026, to approve audited financial results for FY26 and consider a second interim dividend. The company's trading window is closed from April 01 to May 02, 2026.

Laurus Labs Merger & Restructuring

Laurus Labs announced that unsecured creditors of its subsidiaries, Laurus Synthesis and Sriam Labs, have approved a Composite Scheme of Arrangement. This approval marks a significant milestone in the restructuring process. The scheme remains subject to final approval from the NCLT and other regulatory authorities.